Zacks Research Issues Positive Forecast for BPMC Earnings

Blueprint Medicines Co. (NASDAQ:BPMC) – Zacks Research upped their Q4 2026 earnings estimates for shares of Blueprint Medicines in a research report issued to clients and investors on Wednesday, May 21st. Zacks Research analyst A. Chakraborty now expects that the biotechnology company will earn $0.25 per share for the quarter, up from their prior forecast of $0.24. The consensus estimate for Blueprint Medicines’ current full-year earnings is ($1.28) per share. Zacks Research also issued estimates for Blueprint Medicines’ Q1 2027 earnings at $0.48 EPS.

Other equities analysts have also recently issued reports about the company. Wedbush restated an “outperform” rating and set a $128.00 price objective on shares of Blueprint Medicines in a research note on Thursday, May 1st. Jefferies Financial Group started coverage on shares of Blueprint Medicines in a research report on Monday, March 17th. They issued a “buy” rating and a $135.00 price target on the stock. Needham & Company LLC decreased their price target on shares of Blueprint Medicines from $133.00 to $130.00 and set a “buy” rating for the company in a report on Monday, April 28th. Morgan Stanley started coverage on shares of Blueprint Medicines in a research note on Thursday, March 20th. They set an “equal weight” rating and a $100.00 price objective on the stock. Finally, Piper Sandler raised their target price on shares of Blueprint Medicines from $109.00 to $119.00 and gave the stock a “neutral” rating in a report on Monday, January 27th. Five analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $126.56.

Blueprint Medicines Trading Up 1.2%

NASDAQ:BPMC opened at $101.50 on Friday. Blueprint Medicines has a 52 week low of $73.04 and a 52 week high of $121.90. The company has a quick ratio of 2.80, a current ratio of 2.85 and a debt-to-equity ratio of 1.15. The company has a market cap of $6.56 billion, a PE ratio of -93.98 and a beta of 0.83. The business’s 50 day moving average is $90.77 and its two-hundred day moving average is $94.66.

Blueprint Medicines (NASDAQ:BPMC) last issued its quarterly earnings results on Thursday, May 1st. The biotechnology company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.32). The company had revenue of $149.41 million for the quarter, compared to the consensus estimate of $158.31 million. Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. The business’s revenue for the quarter was up 55.5% on a year-over-year basis. During the same period in the previous year, the business posted $1.40 EPS.

Insider Activity

In other Blueprint Medicines news, COO Christina Rossi sold 2,274 shares of the stock in a transaction on Monday, May 19th. The stock was sold at an average price of $100.51, for a total transaction of $228,559.74. Following the completion of the transaction, the chief operating officer now directly owns 64,718 shares of the company’s stock, valued at approximately $6,504,806.18. This trade represents a 3.39% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Ariel Hurley sold 3,203 shares of Blueprint Medicines stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $92.62, for a total value of $296,661.86. Following the transaction, the insider now owns 18,270 shares in the company, valued at approximately $1,692,167.40. This trade represents a 14.92% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 12,777 shares of company stock valued at $1,256,490. Company insiders own 4.21% of the company’s stock.

Institutional Trading of Blueprint Medicines

Several institutional investors have recently modified their holdings of BPMC. SG Americas Securities LLC raised its position in Blueprint Medicines by 69.7% in the fourth quarter. SG Americas Securities LLC now owns 4,277 shares of the biotechnology company’s stock worth $373,000 after acquiring an additional 1,756 shares in the last quarter. Fifth Third Bancorp grew its stake in shares of Blueprint Medicines by 207.5% in the 4th quarter. Fifth Third Bancorp now owns 3,075 shares of the biotechnology company’s stock worth $268,000 after purchasing an additional 2,075 shares during the last quarter. KBC Group NV grew its stake in shares of Blueprint Medicines by 63.9% in the 4th quarter. KBC Group NV now owns 2,625 shares of the biotechnology company’s stock worth $229,000 after purchasing an additional 1,023 shares during the last quarter. R Squared Ltd bought a new stake in shares of Blueprint Medicines in the 4th quarter worth approximately $51,000. Finally, China Universal Asset Management Co. Ltd. lifted its stake in Blueprint Medicines by 10.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 13,470 shares of the biotechnology company’s stock valued at $1,175,000 after purchasing an additional 1,287 shares during the last quarter.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.